Synairgen plc (LON:SNG – Get Rating)'s stock price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 12.55 ($0.15) and traded as low as GBX 9 ($0.11). Synairgen shares last traded at GBX 9 ($0.11), with a volume of 897,679 shares changing hands.
Synairgen Stock Down 6.5 %
The company has a fifty day simple moving average of GBX 12.55 and a 200-day simple moving average of GBX 16.22. The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.09. The firm has a market cap of £18.12 million, a P/E ratio of -69.23 and a beta of -2.20.
Synairgen Company Profile
(Get Rating)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
See Also
- First Republic Bank Hits New Low, Dimon Pushes for More Cash
- Mullen Automotive: Investment? No. Compelling Speculation, Yes
- GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
- General Mills Retreats To Buy Zone Ahead Of Earnings
- Foot Locker: Slow And Steady Wins The Race
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
在週一的交易中,Synairgen plc(倫敦股票代碼:SNG-GET Rating)的股價跌破了50日移動均線。該股的50日移動均線為12.55英鎊(0.15美元),最低交易價格為9英鎊(0.11美元)。Synairgen的股票最新交易價格為9英鎊(0.11美元),成交量為897,679股。
Synairgen股價下跌6.5%
該公司的50日簡單移動均線為12.55英鎊,200天簡單移動均線為16.22英鎊。該公司的速動比率為6.35,流動比率為6.35,債務權益比為0.09。該公司的市值為1812萬GB,本益比為-69.23,貝塔係數為-2.20。
Synairgen公司簡介
(獲取評級)
Synairgen plc發現和開發治療呼吸系統疾病的藥物。該公司開發的產品有:治療新冠肺炎的乙型吸入型幹擾素SG001;治療感冒和流感引起的哮喘的乙型幹擾素吸入劑;治療或預防慢性阻塞性肺病的乙型幹擾素第二階段臨床試驗;以及治療特發性肺纖維化的LXL2抑制劑。
另請參閱
- First Republic Bank創新低,戴蒙推動更多現金
- 馬倫汽車:投資?不是的。令人信服的猜測,是的
- GBTC:以58美分的面值購買位元幣的唯一地方
- 通用磨坊在盈利之前撤退到購買區
- 腳鎖:穩紮穩打贏得比賽
接受Synairgen Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synairgen和相關公司的最新新聞和分析師評級的每日簡明摘要。